The increasing potency of immunosuppression (IS) agents resulted in significantly
decreased rates of steroid resistant rejection and rejection related graft loss in liver …

The calcineurin‐inhibitor tacrolimus (Tac) provides an acceptable balance between
prevention of allograft rejection and drug‐related adverse effects, making it the standard of …

The evolution of kidney allograft survival remains insufficiently studied in the context of the
changing donor and recipient demographics. Since European data are lacking we …

Despite more than two decades of use, the optimal maintenance dose of tacrolimus for
kidney transplant recipients is unknown. We hypothesized that HLA class II de novo donor …

Background & Aims HCV-infected patients with cirrhosis achieve high sustained virological
response (SVR) rates with direct-acting antivirals (DAAs) even after hepatic …

Alloimmune risk stratification in renal transplantation has lacked the necessary prognostic
biomarkers to personalize recipient care or optimize clinical trials. HLA molecular mismatch …

Alloimmunity remains a barrier to long-term graft survival that necessitates lifelong
immunosuppressive therapy after renal transplant. Medication nonadherence has been …

ABSTRACT Introduction: Tacrolimus (Tac) is the cornerstone of immunosuppressive therapy
after solid organ transplantation and will probably remain so. Excluding belatacept, no new …

Nirmatrelvir/ritonavir (Paxlovid) consists of a peptidomimetic inhibitor (nirmatrelvir) of the
SARS-CoV-2 main protease and a pharmacokinetic enhancer (ritonavir). It is approved for …

Medication non-adherence (MNA) is a major issue in kidney transplantation and it is
associated with increased risk of rejection, allograft loss, patients' death and higher …